Zealand Pharma enters agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support Metabolic Frontier 2030 strategy

Zealand Pharma enters agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support Metabolic Frontier 2030 strategy

https://aithority.com/machine-learning/zealand-pharma-enters-agreement-with-dcai-to-use-gefion-ai-supercomputer-to-accelerate-drug-discovery-and-support-metabolic-frontier-2030-strategy/

Publish Date: 2026-01-12 03:07:00

Source Domain: aithority.com

• Zealand Pharma partners with DCAI to access Denmark’s Gefion AI supercomputer to advance drug discovery.
• The collaboration aims to boost computational power for complex molecular modeling and peptide simulation to support new drug development.
• The agreement aligns with Zealand Pharma’s Metabolic Frontier 2030 strategy, targeting five new drug launches by 2030 along with a robust clinical pipeline.
• Gefion’s supercomputer infrastructure features over 1,500 NVIDIA GPUs, offering renewable energy-powered computational capabilities tailored for large-scale projects.
• Integration of advanced AI tools is expected to accelerate Zealand Pharma’s research, enhancing the speed and efficiency of drug creation.
• The partnership underscores a significant achievement for DCAI in furthering biotech advancements and bringing innovative metabolic treatments to market faster.